(Q53571993)

15 May 2018

title

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. (English)

1 reference

15 May 2018

27

Sook-Hyang Jeong

1 reference

15 May 2018

Mong Cho

10

object named as

Mong Cho

1 reference

15 May 2018

author name string

Byung Chul Yoo

1

1 reference

15 May 2018

Ju Hyun Kim

2

1 reference

15 May 2018

Young-Hwa Chung

3

1 reference

15 May 2018

Kwan Sik Lee

4

1 reference

15 May 2018

Seung Woon Paik

5

1 reference

15 May 2018

Soo Hyung Ryu

6

1 reference

15 May 2018

Byung Hoon Han

7

1 reference

15 May 2018

Joon-Yeol Han

8

1 reference

15 May 2018

Kwan Soo Byun

9

1 reference

15 May 2018

Heon-Ju Lee

11

1 reference

15 May 2018

Tae-Hun Kim

12

1 reference

15 May 2018

Se-Hyun Cho

13

1 reference

15 May 2018

Joong-Won Park

14

1 reference

15 May 2018

Soon-Ho Um

15

1 reference

15 May 2018

Seong Gyu Hwang

16

1 reference

15 May 2018

Young Soo Kim

17

1 reference

15 May 2018

Youn-Jae Lee

18

1 reference

15 May 2018

Chae Yoon Chon

19

1 reference

15 May 2018

Byung-Ik Kim

20

1 reference

15 May 2018

Young-Suk Lee

21

1 reference

15 May 2018

Jin-Mo Yang

22

1 reference

15 May 2018

Haak Cheoul Kim

23

1 reference

15 May 2018

Jae Seok Hwang

24

1 reference

15 May 2018

Sung-Kyu Choi

25

1 reference

15 May 2018

Young-Oh Kweon

26

1 reference

15 May 2018

Myung-Seok Lee

28

1 reference

15 May 2018

Jong-Young Choi

29

1 reference

15 May 2018

Dae-Ghon Kim

30

1 reference

15 May 2018

Yun Soo Kim

31

1 reference

15 May 2018

Heon Young Lee

32

1 reference

15 May 2018

Kwon Yoo

33

1 reference

15 May 2018

Hee-Won Yoo

34

1 reference

15 May 2018

Hyo-Suk Lee

35

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 May 2007

1 reference

15 May 2018

published in

Hepatology

1 reference

15 May 2018

volume

45

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

1172-1178

1 reference

15 May 2018

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

cites work

1 reference

Hepatitis B virus infection

21 January 2018

1 reference

7 January 2021

Chronic hepatitis B: update of recommendations

1 reference

7 January 2021

Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

7 January 2021

Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents

1 reference

7 January 2021

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

7 January 2021

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

1 reference

7 January 2021

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

1 reference

7 January 2021

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

1 reference

7 January 2021

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

1 reference

7 January 2021

A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Current treatment of chronic hepatitis B: benefits and limitations

1 reference

7 January 2021

Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA.

1 reference

7 January 2021

Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay

1 reference

7 January 2021

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

1 reference

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21629

1 reference

15 May 2018

PubMed ID

17464992

1 reference

15 May 2018